Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-04-23

Clinical Trial Update: Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial results for Sativex (nabiximols) assessing relief of persistent pain in participants with advanced cancer, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sativex (nabiximol)

Snippet

Sponsor: GW Pharmaceuticals Ltd | Conditions: Pain, Advanced Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-04-23